Skip to content

Can HAART prevent SARS?

Kaletra may cause fewer lipid abnormalities than previously thought in HIV-positive

Kaletra leads to significant increases in some blood lipids in HIV-negative men

Fixed-dose ARV combinations: choices and challenges

Unexpected CD4 declines seen on full dose ddI with tenofovir

Tipranavir emergency use programme expands

Tenofovir/FTC once daily tablet ready by 2005

HIV envelope may hold clues to likely treatment response

Diabetes drug and exercise help reduce heart disease risk and improve body shape in HAART patients